PMID- 21374328
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20110304
IS  - 1543-1894 (Print)
IS  - 1543-1894 (Linking)
VI  - 29
DP  - 2000
TI  - Mucosal immunization with DNA vaccines.
PG  - 287-95
LID - 10.1385/1-59259-688-6:287 [doi]
AB  - The mucosal surface area of the gastrointestinal, genitourinary and respiratory 
      tracts is more than 200 times greater than that of the skin and is the primary 
      site of transmission of numerous diseases. The entry of pathogenic organisms at 
      mucosal surfaces can be prevented by mucosal, but not systemic immunity. Vaccines 
      which are delivered by intramuscular (IM) or subcutaneous (SC) injection induce 
      strong systemic responses but generally no mucosal immunity. In contrast, 
      vaccines delivered at mucosal surfaces trigger both mucosal (at local and distant 
      sites) and systemic responses (1,2). Other advantages of mucosal immunization 
      include a broader age range of recipients, the vaccines are easy and non-invasive 
      to administer and there is no risk of needle stick injury and cross contamination 
      (3).
FAU - McCluskie, M J
AU  - McCluskie MJ
AD  - Loeb Research Institute, Ottawa Civic Hospital, Ottawa, Canada.
FAU - Davis, H L
AU  - Davis HL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Med
JT  - Methods in molecular medicine
JID - 101123138
EDAT- 2000/01/01 00:00
MHDA- 2000/01/01 00:01
CRDT- 2011/03/05 06:00
PHST- 2011/03/05 06:00 [entrez]
PHST- 2000/01/01 00:00 [pubmed]
PHST- 2000/01/01 00:01 [medline]
AID - 10.1385/1-59259-688-6:287 [doi]
PST - ppublish
SO  - Methods Mol Med. 2000;29:287-95. doi: 10.1385/1-59259-688-6:287.